Biocon Limited has announced the approval of its Placement Document for a Qualified Institutions Placement (QIP) of equity shares. The Fund Raising Committee meeting held on January 14, 2026, marked a significant step forward in the company's capital raising initiative.

Committee Meeting Details

The Fund Raising Committee convened on January 14, 2026, with the meeting commencing at 10:12 p.m. and concluding at 10:20 p.m. During this brief but crucial session, the committee approved and adopted the Placement Document dated January 14, 2026, in connection with the proposed equity issue.

Qualified Institutions Placement Structure

The QIP involves equity shares with a face value of ₹5 each. The placement is being conducted under multiple regulatory frameworks to ensure comprehensive compliance. The issue falls under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, commonly referred to as the SEBI ICDR Regulations.

Additionally, the placement adheres to specific sections of the Companies Act, 2013, as amended, including:

• Section 23(1)(b)
• Section 42
• Section 62(1)(c)

Regulatory Compliance and Communication

Biocon Limited has fulfilled its regulatory obligations by informing both major stock exchanges about this development. The company communicated with BSE Limited, where its scrip code is 532523, and the National Stock Exchange of India Limited, where it trades under the symbol BIOCON.

The announcement serves as compliance under Regulation 30 and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The company has also made this information available on its official website at www.biocon.com for public access.

Corporate Communication

The formal communication was signed by Rajesh U. Shanoy, Company Secretary and Compliance Officer, who holds ICSI membership number A16328. The document was digitally signed on January 14, 2026, at 22:27:26 +05'30', ensuring authenticity and regulatory compliance.

This development follows previous communications dated January 12, 2026, and January 14, 2026, indicating ongoing progress in the company's fund-raising activities. The approval of the Placement Document represents a key milestone in Biocon's capital market initiatives.

Biocon Limited has successfully completed its Qualified Institutions Placement (QIP), with the Fund Raising Committee announcing the closure and allotment of equity shares on January 14, 2026. The pharmaceutical company raised significant capital through this institutional placement, demonstrating strong investor confidence in its growth prospects.

QIP Details and Pricing Structure

The company's Fund Raising Committee, in its meeting held on January 14, 2026, approved the allocation of shares to qualified institutional buyers. The key parameters of the placement are outlined below:

The total fundraising from this QIP amounts to approximately ₹4,151 crores, calculated based on the allotted shares and issue price. The pricing was determined in accordance with the formula prescribed under Regulation 176(1) of the SEBI ICDR Regulations.

Timeline and Regulatory Compliance

The QIP demonstrated efficient execution with a swift timeline from opening to closure:

• Issue Opening: January 12, 2026
• Issue Closure: January 14, 2026
• Committee Meeting Duration: 10:00 PM to 10:10 PM on January 14, 2026

The Fund Raising Committee's meeting addressed three critical resolutions during the brief 10-minute session. The committee approved the closure of the issue following receipt of application forms and funds in the escrow account from eligible qualified institutional buyers. Additionally, they determined and approved the allocation of shares according to SEBI ICDR Regulations and finalized confirmation of allocation notes to be sent to successful institutional investors.

Regulatory Framework and Approvals

The QIP was conducted under comprehensive regulatory oversight, ensuring compliance with multiple statutory requirements. The placement was executed under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, along with Sections 42, 23(1)(b), and 62(1)(c) of the Companies Act, 2013.

Biocon has fulfilled its disclosure obligations under Regulation 30 and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has made the intimation available on its website at www.biocon.com , ensuring transparency for all stakeholders.

Market Communication

The company formally communicated the QIP completion to both major stock exchanges where its shares are listed. Biocon submitted detailed notifications to BSE Limited (Scrip Code: 532523) and National Stock Exchange of India Limited (Scrip Symbol: BIOCON), maintaining compliance with listing requirements and ensuring proper market disclosure of this significant capital raising activity.